CA2976665A1 - Crystalline forms of a pyrrolopyridine compound - Google Patents

Crystalline forms of a pyrrolopyridine compound Download PDF

Info

Publication number
CA2976665A1
CA2976665A1 CA2976665A CA2976665A CA2976665A1 CA 2976665 A1 CA2976665 A1 CA 2976665A1 CA 2976665 A CA2976665 A CA 2976665A CA 2976665 A CA2976665 A CA 2976665A CA 2976665 A1 CA2976665 A1 CA 2976665A1
Authority
CA
Canada
Prior art keywords
pyrrolo
bromo
cyclopropanecarboxamide
aminopiperidin
pyridin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2976665A
Other languages
English (en)
French (fr)
Inventor
Jeffrey Stults
Christopher M. Lindemann
Keith L. Spencer
Weidong Liu
Joseph LUBACH
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genentech Inc
Array Biopharma Inc
Original Assignee
Genentech Inc
Array Biopharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55521844&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA2976665(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genentech Inc, Array Biopharma Inc filed Critical Genentech Inc
Publication of CA2976665A1 publication Critical patent/CA2976665A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)
CA2976665A 2015-02-26 2016-02-26 Crystalline forms of a pyrrolopyridine compound Abandoned CA2976665A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562121396P 2015-02-26 2015-02-26
US62/121,396 2015-02-26
PCT/US2016/019904 WO2016138458A1 (en) 2015-02-26 2016-02-26 Crystalline forms of a pyrrolopyridine compound

Publications (1)

Publication Number Publication Date
CA2976665A1 true CA2976665A1 (en) 2016-09-01

Family

ID=55521844

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2976665A Abandoned CA2976665A1 (en) 2015-02-26 2016-02-26 Crystalline forms of a pyrrolopyridine compound

Country Status (21)

Country Link
US (2) US20160251350A1 (https=)
EP (1) EP3262042A1 (https=)
JP (1) JP2018506562A (https=)
KR (1) KR20170118762A (https=)
CN (1) CN107406447A (https=)
AR (1) AR103801A1 (https=)
AU (1) AU2016225070A1 (https=)
BR (1) BR112017018230A2 (https=)
CA (1) CA2976665A1 (https=)
CL (1) CL2017002180A1 (https=)
CO (1) CO2017009662A2 (https=)
CR (1) CR20170439A (https=)
HK (1) HK1246786A1 (https=)
IL (1) IL254115A0 (https=)
MA (1) MA41599A (https=)
MX (1) MX2017010888A (https=)
PE (1) PE20171327A1 (https=)
PH (1) PH12017501532A1 (https=)
RU (1) RU2017133093A (https=)
SG (1) SG11201706824TA (https=)
WO (1) WO2016138458A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115385871A (zh) * 2019-01-29 2022-11-25 沪亚生物国际有限公司 舒欣啶盐
EP3923948A4 (en) * 2019-02-12 2022-11-16 Impact Biomedicines, Inc. CRYSTALLINE SHAPES OF A JAK2 INHIBITOR

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
AR071717A1 (es) 2008-05-13 2010-07-07 Array Biopharma Inc Pirrolo[2,3-b]piridinas inhibidoras de quinasas chk1 y chk2,composiciones farmaceuticas que las contienen,proceso para prepararlas y uso de las mismas en el tratamiento y prevencion del cancer.
US8481557B2 (en) * 2009-04-11 2013-07-09 Array Biopharma Inc. Method of treatment using checkpoint kinase 1 inhibitors
ES2621857T3 (es) * 2010-11-16 2017-07-05 Array Biopharma, Inc. Combinación de inhibidores de la cinasa 1 de punto de control e inhibidores de la cinasa WEE1
KR102325163B1 (ko) * 2013-08-22 2021-11-11 제넨테크, 인크. 화합물의 제조 방법
WO2015027090A1 (en) * 2013-08-22 2015-02-26 Genentech, Inc. Intermediates and processes for preparing compounds

Also Published As

Publication number Publication date
CL2017002180A1 (es) 2018-03-16
KR20170118762A (ko) 2017-10-25
HK1246786A1 (zh) 2018-09-14
PE20171327A1 (es) 2017-09-12
WO2016138458A1 (en) 2016-09-01
IL254115A0 (en) 2017-10-31
AR103801A1 (es) 2017-06-07
SG11201706824TA (en) 2017-09-28
PH12017501532A1 (en) 2018-02-05
MA41599A (fr) 2018-01-02
AU2016225070A1 (en) 2017-09-07
US20160251350A1 (en) 2016-09-01
US20180282324A1 (en) 2018-10-04
BR112017018230A2 (pt) 2018-04-17
JP2018506562A (ja) 2018-03-08
EP3262042A1 (en) 2018-01-03
CR20170439A (es) 2018-01-08
MX2017010888A (es) 2017-12-15
RU2017133093A (ru) 2019-03-26
CN107406447A (zh) 2017-11-28
CO2017009662A2 (es) 2018-02-28
RU2017133093A3 (https=) 2019-08-23

Similar Documents

Publication Publication Date Title
CN116891487A (zh) 作为kras g12d抑制剂的杂环化合物
TW202126651A (zh) 吡啶酮化合物及使用方法
CN102753554A (zh) Raf抑制剂化合物及其使用方法
JP2017530155A (ja) 化合物
AU2009204025B2 (en) Hydroxylated pyrimidyl cyclopentanes as AKT protein kinase inhibitors
AU2009204019B2 (en) Hydroxylated pyrimidyl cyclopentane as AKT protein kinase inhibitor
US20180282324A1 (en) Crystalline forms of a pyrrolopyridine compound
EA028059B1 (ru) Твердые формы n-((s)-2,3-дигидроксипропил)-3-(2-фтор-4-йодфениламино)изоникотинамида
CA2939848A1 (en) Oxepan-2-yl-pyrazol-4-yl-heterocyclyl-carboxamide compounds and methods of use
TWI633107B (zh) 作為ｐａｒｐ抑制劑的稠合四或五環二氫二氮呯并咔唑酮
CN113583020B (zh) 一种jak2抑制剂及应用
US20250353847A1 (en) Crystalline forms of an akric3 dependent kars inhibitor
TWI588144B (zh) 作爲ｐａｒｐ抑制劑的稠合四或五環吡啶並酞嗪酮
US20160152574A9 (en) Hydroxylated pyrimidyl cyclopentanes as akt protein kinase inhibitors
WO2023057545A1 (en) Substituted chalcones
CN116813646A (zh) 取代桥环类抑制剂及其制备方法和应用
HK1150201B (en) Hydroxylated pyrimidyl cyclopentanes as akt protein kinase inhibitors
HK1150201A (en) Hydroxylated pyrimidyl cyclopentanes as akt protein kinase inhibitors
BR112018076443B1 (pt) Processo de preparação de formas cristalinas de um composto de triazolopirimidina
HK1149269B (en) Hydroxylated pyrimidyl cyclopentane as akt protein kinase inhibitor

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20210831